ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Reviewers Find I-ELCAP Is A Trial That Never Ends, With 90 Percent of Consent Forms Unobtainable

April 29, 2011

FDA Approves Medication For Smoking Cessation

May 26, 2006

New RFAs on Retinoids & Carotenoids, Tobacco, NMR Research Resistance

July 27, 1984

Professional Societies: ASCO Foundation Formed to Support Fellowship Awards

June 11, 1999

NIH Seeking More Women, Minorities On Committees

November 9, 1979

Firm To Collaborate With R. W. Johnson On Vaccines.

December 1, 2000